Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03796546
Other study ID # PIPSEC - 01
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 22, 2019
Est. completion date October 7, 2020

Study information

Verified date November 2020
Source IDbyDNA, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Prospective, multi-site, study to evaluate the diagnosis rate of DNA and RNA sequencing of cerebrospinal fluid for identification of pathogens directly in patients who have already had a spinal tap to evaluate for infection and were found to have a pleocytosis. Diagnostic rate and clinical utility of concurrent standard testing will be compared to diagnostic rate and clinical utility of DNA and RNA sequencing.


Description:

IDbyDNA, Inc. has developed a robust sequencing reference database for viruses, bacteria, fungi and parasites and developed novel analysis methods to analyze next-generation (NGS) sequencing data to rapidly identify infectious agents. This technology suite, known as the Explify™ platform, holds the promise to improve patient care and efficiently guide provider treatment planning for those suffering from infectious disease. The PIPSEC trial, developed by pediatric physicians specializing in genomic medicine, is intended to facilitate the acquisition of high quality and clinically annotated biospecimens for the purpose of research discovery. This project intends to advance metagenomics, microbial genetics, bioinformatics and data analytics, for pathogen detection utilizing cerebral spinal fluid (CSF) specimens to contribute to the diagnosis of infectious agents impacting the central nervous system among pediatric patients. Clinically annotated specimens will facilitate continued development and validation of the Explify test and its clinical utility for providers treating central nervous system (CNS) infections. The primary objective is to assess clinical utility of the Explify test compared to concurrent standard of care testing to identify pathogens from CSF fluid within a pediatric patient population.


Recruitment information / eligibility

Status Completed
Enrollment 71
Est. completion date October 7, 2020
Est. primary completion date October 7, 2020
Accepts healthy volunteers No
Gender All
Age group N/A to 17 Years
Eligibility Inclusion Criteria: - Age 0-17 years of age (not yet 18) - Clinical evaluation for CNS infection - CSF white blood cell count (WBC) > 15 cells/µL when there are less than 5000 RBCs on same - Admitted to a participating study site - CSF obtained per standard protocol - 1 mL of appropriately stored CSF is available following completion of all standard of care testing Exclusion Criteria: - CSF Red blood cell (RBC) count > 5000 cells/µL on same CSF sample as with pleocytosis - Unable to obtain consent

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Nicklaus Children's Hospital Miami Florida
United States CHOC Children's Hospital Orange County Orange California
United States Rady Children's Hospital San Diego California

Sponsors (2)

Lead Sponsor Collaborator
IDbyDNA, Inc. Rady Children's Hospital, San Diego

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Post-Hoc Analysis - Economic Evaluation (1) Economic evaluation of cost of standard of care testing compared to economic cost of NGS testing:
Determination of what diagnosis made could have been made with best possible clinical tests currently available.
24 months
Other Post-Hoc Analysis - Economic Evaluation (2) Cost analysis of what best available testing would have cost. 24 months
Other Post-Hoc Analysis - Host Response RNA sequencing to determine if there is a specific host response to either specific infectious or noninfectious etiologies. 24 months
Primary Diagnostic Rate Comparison of the sensitivity, specificity, positive and negative predictive values of IDbyDNA NGS results with the Explify diagnostic platform compared with standard care. 24 months
Secondary Clinical Utilization Change of Management resulting from NGS diagnosis versus diagnosis based on standard of care. Change of Management is a binary (yes or no) based on assignments made by the PI or designee at each site using the following domains:
Diagnosis specific pharmacological treatment
Diagnosis specific management
Diagnosis specific supportive interventions A change in any of these domains will be considered a change of clinical management for utilization purposes.
24 months
See also
  Status Clinical Trial Phase
Completed NCT04529421 - Assocation Between In-person Instruction and COVID-19 Risk
Recruiting NCT04081792 - Optimal Antibiotics for Operated Diabetic Foot Infections N/A
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Recruiting NCT04674657 - Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Recruiting NCT00342589 - New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Completed NCT03296423 - Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly Phase 4
Withdrawn NCT04217252 - Clinical Application of High-throughput Sequencing Technology for the Diagnosis of Patients With Severe Infection N/A
Recruiting NCT02899143 - Short-course Antimicrobial Therapy in Sepsis Phase 2
Recruiting NCT02905552 - Myelodysplasic Syndromes and Risk Factors for Infection N/A
Withdrawn NCT02904434 - Gastrointestinal Implications of Voriconazole Exposure
Active, not recruiting NCT02768454 - Antimicrobials Stewardship by Pharmacist N/A
Completed NCT02219776 - Decreasing Infection In Arthroscopic Shoulder Surgery N/A
Completed NCT02210169 - RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates N/A
Recruiting NCT02098226 - Evaluation of MALDI Biotyper CA System for Detection of Gram- and Gram+ Bacteria and Yeasts N/A
Completed NCT01846832 - A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection Phase 3
Terminated NCT01441206 - Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants Phase 1
Completed NCT01434797 - Value of PET/CT Imaging in the Diagnosis of Permanent Central Venous Catheters Infection
Completed NCT01159834 - Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital) N/A

External Links